Is Clarithromycin a Potential Treatment for Cachexia in People With Lung Cancer?
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study aims to identify if clarithromycin (CLM) has potential as a widely available and
inexpensive treatment for cachexia (the loss of muscle mass) in people with non-small cell
lung cancer (NSCLC). Half the participants will receive clarithromycin and half will receive
a placebo.